Is it possible to treat melanoma by intercepting the CXCR4/CXCL12 pathway?

We present an overview of the CXCR4/CXCL12 axis in cancer progression and explain its role in the melanoma microenvironment in this paper. Furthermore, we investigate CXCR4's predictive usefulness as a possible biomarker for monitoring melanoma progression. Finally, we discuss the most recent research and clinical trials on CXCR4 inhibitors, emphasizing their efficacy and limits. We hope to improve the quality of life for melanoma patients by better understanding the role of CXCR4 and investigating novel therapeutic options.PMID:38704961 | DOI:10.1016/j.cyto.2024.156629
Source: Cytokine - Category: Molecular Biology Authors: Source Type: research